1122090-71-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-bromo-6-methylpicolinate is used as a drug development intermediate for the creation of new pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of various medicinal compounds.
Used in Medicinal Chemistry:
Ethyl 5-bromo-6-methylpicolinate is used as a building block in medicinal chemistry for the development of biologically active molecules. Its ability to be modified and incorporated into complex molecular structures makes it a valuable tool in the design of new drugs.
Used in Agrochemical Production:
Ethyl 5-bromo-6-methylpicolinate is used as an intermediate in the synthesis of agrochemicals, such as insecticides and pesticides. Its chemical properties make it suitable for the development of effective and targeted pest control solutions.

Upstream product

• 64-17-5 ethanol 
• 137778-20-2 3-bromo-2-methyl-6-pyridinecarboxylic acid 
• 1122090-67-8 3-bromo-2-methyl-6-vinylpyridine 
• 1173897-86-3 5-bromo-6-methylpyridine-2-carbonitrile 

Relevant academic research and scientific papers

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.